Bright Roche results reinforce the ‘focus on innovation’
This article was originally published in Scrip
Executive Summary
Hoffmann-La Roche has bucked the gloomy trend among pharma companies with first half results that showed a 4% rise in pharmaceutical sales globally, despite a 7% drop in sales in Europe. Asked by analysts to account for its relatively good performance in Europe, CEO Severin Schwan confirmed that the impact of European pricing constraints on Roche in Europe– a 1% reduction quarter on quarter – was less than half of that other companies were reporting.